Novadip Biosciences

Novadip Biosciences is a private, clinical-stage biotech developing a new class of regenerative tissue products derived from adipose (fat) stem cells. The company's core technology platform aims to generate 3D tissues that mimic the natural healing environment, targeting critical challenges in orthopedics and reconstructive surgery. With a pipeline led by programs for congenital pseudarthrosis of the tibia (CPT) and spine fusion, Novadip is positioning itself in the high-growth cell and gene therapy sector. The company operates from Mont-Saint-Guibert, Belgium, and is likely pre-revenue, relying on partnerships and investment to advance its clinical programs.

Proprietary platform using adipose-derived stem cells to generate 3D, living tissue constructs for bone and tissue regeneration.

Competition includes large medical device companies (Medtronic, Stryker, Zimmer Biomet) with bone graft products, and other regenerative medicine firms developing stem cell and growth factor-based therapies. Novadip aims to differentiate with its 3D, tissue-mimicking constructs designed for a single administration.